草鱼、中华鳖IL—2活性影响因素的研究

结果显示：当年草鱼种和中华鳖脾细胞培养上清液中能检测出IL－2活性,而且1龄以上草鱼、中华鳖的IL－2活性高于当年孵化的草鱼和中华鳖。草鱼、中华鳖脾细胞在25℃培养温度条件下,其上清液中IL－2活性最高,35℃次之,15℃最低。因此,草鱼、中华鳖IL－2活性在一定范围内是随着年龄增加而增强和依赖温度的。通过小鼠胞腺细胞增殖和对小鼠L929细胞杀伤率的实验表明37℃比25℃检测温度下所测的IL－2活性高,而中华鳖胸腺细胞增殖实验却显示25℃检测温度下IL－2活性高于37℃。本文讨论了年龄、温度对免疫反应影响的机理。     

白介素-2促进RC-4B/C垂体瘤细胞系增殖

采用细胞培养方法,以＾３Ｈ－ＴｄＲ掺入率反映细胞增殖水平,研究了白介素－２（ＩＬ－２）对大鼠源的ＲＣ－４Ｂ／Ｃ垂体瘤细胞系增殖的影响,并初步分析了ＩＬ－２的作用机制。结果表明：⑴ＩＬ－２（１０－１０００Ｕ／ｍｌ）剂量依赖性地显著提高ＲＣ－４８／Ｃ细胞＾３Ｈ－ＴｄＲ掺入率。⑵特异性酪氨酸蛋白激酶（ＰＴＫ）抑制剂ｔｙｒｐｈｏｓｔｉｎ（１μｍｏｌ／Ｌ）可明显降低ＲＣ－４Ｂ／Ｃ细胞＾３Ｈ－ＴｄＲ掺入率,并     

创伤后巨噬细胞对T细胞白介素2及白介素2受体α基因表达的直…

以２５μｇ／ｍｌ的丝裂霉素Ｃ处理巨噬细胞３０ｍｉｎ,可阻断巨噬细胞白介素１（ＩＬ－１）、白介素６（ＩＬ－６）、肿瘤坏死因子（ＴＮＦ）及前列腺素Ｅ２（ＰＧＥ２）的合成与分泌。创伤小鼠巨噬细胞经丝裂霉素Ｃ处理后,可明显抑制正常Ｔ细胞白介素２（ＩＬ－２）ｍＲＮＡ及ＩＬ－２受体（ＩＬ－２Ｒ）α ｍＲＮＡ水平,并增强Ｔｓ细胞的抑制活性。去除Ｔ细胞中Ｔｓ细胞可使巨噬细胞的抑制作用消失。表明创伤后巨噬细胞可通过     

白细胞介素2对大鼠垂体前叶细胞雌激素受体蛋白含量和基因表达的影响

采用原代无血清细胞培养技术结合免疫组织（细胞）化学和半定量反转录－ＰＣＲ方法,观察白细胞介素２（ＩＬ－２）对大鼠垂体前叶雌激素受体（ＥＲ）蛋白含量和基因表达的影响,以探讨ＩＬ－２和ＥＲ在大鼠重体前叶的相互关系。结果显示：在大鼠垂体前叶细胞有ＩＬ－２受体表达。在无血清培养条件下,ＩＬ－２能增加ＥＲα蛋白含量,促进ＥＲα基因表达,而对ＥＲβ的作用正好相反,ｒｈＩＬ－２（１０μｇ／Ｌ）作用４８ｈ后,ＥＲ     

bcl—2和IL—1和TNFα表达的调节作用初探

通过将反义ｂｃｌ－２基因转梁于Ｕ９３７细胞,建立了Ｂｃｌ－２蛋白表达受抑的Ｕ９３７细胞模型,证实了模型细胞的增殖和存活表型授课和线菌素Ｄ－结晶紫试验和ＥＬＩＳＡ检测表明模型细胞上清中ＴＮＦα的活性和含量无明显变化,小鼠胸腺细胞增殖试验表明模型细胞上清中ＩＬ－１活性升高,提示ｂｃｌ－２的表达对ＴＮＦα的表达无明显影响,但可能在一定程度上抑制了ＩＬ－１的表达或活性。     

白细胞介素—2对大鼠离体垂体前叶细胞增殖的影响

本工作采用大鼠垂体前叶（ＡＰ）细胞原代培养方法,以＾３Ｈ－ＴｄＲ掺入率反映细胞增殖水平,研究了ＩＬ－２对ＡＰ细胞增殖的影响。结果表明：（１）ＩＬ－２（１０￣５００Ｕ／ｍｌ）明显促进性大鼠包括妊娠大鼠的ＡＰ细胞的增殖,而抑制雄性大鼠ＡＰ细胞的增殖。（２）雄性大鼠行卵巢切除（ＯＶＸ）二周后,ＩＬ－２对其ＡＰ细胞增殖的影响反转为抑制效应;若在卵巢切除二周内,每日给予ＯＶＸ大鼠皮下注射５μｇ苯甲酸雌二醇,     

人白细胞介素－2的两个部分拮抗剂

通过定点诱变技术得到６个生物活性剧烈下降的人白细胞介素－２（ＩＬ－２）突变体,其中两个突变体即１５Ｖａｌ－ＩＬ－２和１２６Ａｓｐ－ＩＬ－２可以在一定浓度范围内使ＩＬ－２的生物效应降低。在对高亲和力ＩＬ－２受体（ＩＬ－２Ｒ）的竞争抑制实验中,１５Ｖａｌ－ＩＬ－２和１２６Ａｓｐ－Ｉｌ－２又表现了一定的竞争能力。这些结果表明１５Ｖａｌ－ＩＬ－２和１２６Ａｓｐ－ＩＬ－２可部分拮抗天然ＩＬ－２的作用。结合Ｉ     

LC－CW的抗肿瘤作用及其机理的研究

提取干酪乳酸杆菌细胞壁成分（ＬＣ－ＣＷ）,研究其抗肿瘤作用及其机理。结果表明：１００μｇＬＣ－ＣＷ,ｉｐ,连续４天,可明显抑制小鼠Ｓ１８腹水瘤移植物的生长,抑瘤率为５４％。增强ＩＬ－２诱导的ＬＡＫ杀伤活性,可明显促进小鼠ＮＫ杀伤活性,明显促进小鼠Ｔ细胞转化,促进ＣｏｎＡ和ＰＨＡ－Ｐ诱导的ＩＬ－２产生,促进ＳＩＬ－２Ｒ的减少。研究结果表明ＬＣ－ＣＷ是一种重要的抗肿瘤免疫调节因子。     

IL－2／LAK对荷瘤机体细胞免疫功能的改善

本实验将ＩＬ－２／ＬＡＫ应用于荷瘤鼠,对荷瘤机体的细胞免疫功能（鼠脾ＮＫ细胞活性、鼠脾ＩＬ－２产生能力及腹腔巨噬细胞吞噬功能）进行动态观察。结果证实：ＩＬ－２／ＬＡＫ能在一定程度上改善荷瘤机体的细胞免疫功能,并能够有一定程度的阻抑荷瘤机体的细胞免疫功能降低。同时探讨了ＩＬ－２／ＬＡＫ在肿瘤治疗中,提高细胞功能的机理。     

LC—CW的抗肿瘤作用及其机理的研究

提取干酪乳酸杆菌细胞壁成分,研究其抗肿瘤作用及其机理。结果表明：１００μｇ－ＬＣ－ＣＷ,ｉｐ,连续４天,可明显抑制小鼠Ｓ１８０腹水瘤移植物的生长,抑瘤率为５４％。增强ＩＬ－２诱导的ＬＡＫ杀伤活性。可明显促进小鼠ＮＫ杀伤活性,明显促进小鼠Ｔ细胞转化,促进ＣｏｎＡ和ＰＨＡ－Ｐ诱导的ＩＬ－２产生,促进ＳＩＬ－２Ｒ的减少。     

草鱼、中华鳖T淋巴细胞表面抗原的研究

以草鱼脑组织、中华鳖脑组织和胸腺细胞为抗原制备兔抗草鱼脑血清（RACBS）、兔抗顺华鳖脑血清（RATBS）和兔抗中华鳖胸腺细胞血清（RATTS）。补体依赖性细胞毒试验和不同组织对RATBS、RATTS的吸收试验结果表明：中华鳖胸腺细胞和脑组织均存在Thy1抗原（亦称脑组织抗原或胸腺-脑组织T细胞抗原）;草鱼脑组织缺乏Thy1抗原。应用间接酶标免疫组化染色技术显示：Thy1抗原阳性反应物沉淀于中华鳖胸腺细胞和外周一部分淋巴细胞表面,进一步用抗人白细胞分化抗原CD4、CD8单克隆抗体进行免疫组化交叉反应提示中华鳖淋巴细胞膜上含有与人类T淋巴细胞表面抗原CD4、CD8类似结构的物质。本文讨论了Thy1抗原、CD抗原的出现及其意义。探讨了淋巴细胞异质性及RATBS、RATTS的特异性和作用。     

Preparation and characterization of polyclonal and monoclonal antibodies against human interleukin 1 alpha (IL 1 alpha)

Polyclonal and monoclonal anti-human IL 1 alpha antibodies (Ab) have been established. These Ab neutralized human recombinant IL 1 alpha (rIL 1 alpha) activity effectively, but did not interfere with human rIL 1 beta, murine rIL 1 alpha, or human rIL 2 activity. Fifty percent of rIL 1 alpha activity (25 U/ml, or 2.5 ng/ml) was neutralized by less than 0.06 microgram/ml of rabbit anti-IL 1 alpha Ab (R-38.3G) and by less than 0.13 microgram/ml of monoclonal Ab (clone 28(3B1], respectively. In other experiments, 10 micrograms/ml of rabbit anti-IL 1 alpha Ab could effectively neutralize 50% of 2000 U of rIL 1 alpha activity, and the same amount of monoclonal Ab neutralized 50% of 500 U/ml of rIL 1 alpha activity. Not only IL 1 alpha activity in the thymocyte costimulator assay, but also IL 1-dependent IL 2 production by a human leukemic cell line, HSB.2 subclone, were blocked by these polyclonal or monoclonal Ab. In addition, pI 4.9 IL 1 activity produced by the myelomonocytic cell line THP-1 and by the Epstein-Barr virus-transformed B cell lines, were neutralized by these Ab, suggesting that these cell lines also produce IL 1 alpha. The specificity of these polyclonal and monoclonal Ab was further confirmed by immunochemical method (Western blotting), in which anti-IL 1 alpha Ab reacted with rIL 1 alpha in a specific manner. Furthermore, an enzyme-linked immunosorbent assay system has been developed that can detect low levels of IL 1 alpha activity (less than 0.3 ng/ml or less than 3 U/ml), which is still less sensitive than thymocyte comitogenic assay and considerably less sensitive than the D10 assay. Finally, anti-IL 1 alpha Ab-conjugated affinity columns were prepared, by which IL 1 alpha activity, but not IL 1 beta activity, was specifically adsorbed and eluted effectively.     

Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation

The anterior chamber of the eye is an immunologically privileged site in which allografts survive longer than at other body sites. In this regard, it is relevant that aqueous humor (AH) inhibits lymphocyte proliferation. In order to analyze AH for specific substances that inhibit thymocyte proliferation, samples of human AH, murine AH, and rhesus monkey AH were added to cultures of thymocytes stimulated by IL-1 or IL-2 in the presence of PHA. All samples of AH tested had potent inhibitory activity on thymocyte proliferation in this system. Inhibitory activity was lost by heating AH to 80 degrees C for 1 h. Dialysis of murine AH indicated that species smaller than 3500 Da were capable of mediating this activity; we have termed the factor(s) responsible for this "small inhibitory factor(s) of AH." Retentate, containing species larger than 3500 Da, retained inhibitory activity, but less than nondialyzed AH. Assays for PGE2 demonstrated that murine and human AH contained small quantities of PGE2. These quantities were insufficient to inhibit thymocyte proliferation in our assay system. Furthermore, AH from mice treatend with indomethacin had full inhibitory activity. Assays for transforming growth factor beta (TGF-beta) after acid activation demonstrated significant quantities of latent TGF-beta within human and murine AH which could be largely neutralized by antisera to TGF-beta. Active TGF-beta "activity" was also present without acid activation in samples of AH at a level approximately 20% that of latent TGF-beta. However, most of this "activity" could not be neutralized by antisera to TGF-beta. AH contains factors capable of limiting thymocyte proliferation.     

A synergistic interaction of IL-6 and IL-1 mediates the thymocyte-stimulating activity produced by recombinant IL-1-stimulated fibroblasts

We characterized the ability of normal human lung fibroblasts to elaborate thymocyte-stimulating activity, spontaneously, and in response to rIL-1. Supernatants from unstimulated fibroblasts did not contain thymocyte-stimulating activity, whereas supernatants from fibroblasts incubated with rIL-1 alpha or rIL-1 beta contained more thymocyte-stimulating activity than could be accounted for by passively transferred rIL-1 alone. This heightened thymocyte-stimulating activity was mediated by fibroblast-derived IL-6 inasmuch as it was neutralized by anti-serum against human rIL-6, and rIL-1-stimulated fibroblasts to accumulate messenger RNA for IL-6 and produce soluble IL-6 protein. However, IL-6 alone could not account for the intensity of this effect because rIL-6 only weakly stimulated thymocyte proliferation. In addition, antisera against the rIL-1 moiety that was used to prepare the supernatant had different effects on supernatants that contained and did not contain active IL-6. In the presence of IL-6 these antisera caused a greater decrease in thymocyte-stimulating activity than could be accounted for by passively transferred rIL-1 alone. When the IL-6 was neutralized the remaining thymocyte-stimulating activity could be quantitatively accounted for and neutralized by antisera against the rIL-1 that was passively transferred. Furthermore, rIL-6 and rIL-1 (alpha or beta) synergized in stimulating thymocyte proliferation. Thus, rIL-1 stimulates fibroblasts to produce a thymocyte-stimulating activity that is largely mediated by a synergistic interaction of fibroblast-derived IL-6 and IL-1. These findings suggest that fibroblast production of IL-6 may mediate or amplify some of the tissue effects of IL-1. In addition they suggest that biologic effects previously attributed to IL-1 may be due to IL-6 alone or the concerted action of IL-1 and IL-6.     

Monoclonal antibodies to human recombinant interleukin 1 (IL 1)beta: quantitation of IL 1 beta and inhibition of biological activity

Monoclonal antibodies (McAb) were developed to the Mr 17,500 form of human recombinant interleukin 1, IL 1 beta. Four McAb have been identified that inhibit the biological activity of IL 1 beta. McAb H34 and H67, at 1 microgram/ml (6 X 10(-9) M), completely inhibit the capacity of 1 ng/ml (6 X 10(-11) M) recombinant IL 1 beta to stimulate the proliferation of murine thymocytes or human fibroblasts in vitro. McAb H6 and H21 are approximately 10-fold less potent, and completely inhibit IL 1 beta activity at 10 micrograms/ml (6 X 10(-8) M) in both assays. The McAb do not have a significant effect on the biological activity of human recombinant IL 1 alpha in either assay. These McAb block the binding of recombinant [125I]IL 1 beta to IL 1 receptors on mouse 3T3 fibroblasts and have affinity constants for IL 1 beta in the range of 10(9) to 10(10) liters/mol. Competition studies suggest that two nonoverlapping epitopes on the IL 1 beta molecule are recognized by the McAb. H6 and H34 recognize one epitope, and H21 and H67 another. McAb H6 and H67 have been used together in a two-site ELISA to detect IL 1 beta. The sensitivity of the ELISA, which is 15 pg/ml (0.86 pM), approaches the limit of sensitivity of the thymocyte proliferation assay. The ELISA and thymocyte proliferation assay were used to quantitate IL 1 beta in E. coli LPS-stimulated human monocyte culture supernatants (HMCS). The level of IL 1 beta detected by ELISA in culture supernatants from eight donors ranged from 1.7 to 5.6 ng/ml, with a mean value of approximately 3 ng/ml. By comparison, the thymocyte proliferation assay gave levels of IL 1 in HMCS that were eight fold higher when quantitated by using recombinant IL 1 beta as a standard. This discrepancy with the bioassay used was reflected by the three fold higher maximum stimulation of thymocyte proliferation by HMCS as compared with recombinant IL 1 alpha or IL 1 beta, and only 45% inhibition of HMCS IL 1 activity by McAb. Thus, factors other than IL 1 beta account for the IL 1-like activity in monocyte culture supernatant as measured by the bioassay. The ILB1 McAb and ELISA allow for the first time-sensitive, accurate, and convenient quantitation of IL 1 beta levels in biological fluids or specimens.     

Expression in Escherichia coli of fully active recombinant human IL 1 beta: comparison with native human IL 1 beta

Although complementary DNA (cDNA) encoding human interleukin 1 beta (IL 1 beta) have been cloned in several laboratories, there are as yet no data demonstrating that recombinant IL 1 beta (rIL 1 beta) molecules expressed from such cDNA are faithful, fully active replicas of the native protein secreted by human monocytes. To this purpose, cDNA sequences corresponding to the exact NH2-terminus and amino acid sequence of mature, monocyte-derived human IL 1 beta were placed under control of the inducible trp-lac (TAC) fusion promoter and were expressed in E. coli strain JM105. rIL 1 beta was purified to homogeneity by high pressure liquid chromatography (HPLC). Yields of 10 to 20 mg of rIL 1 beta/liter/10(11) cells were obtained. Purified rIL 1 beta was then compared in a number of biochemical and biologic assays to purified native IL 1 beta. Native and rIL 1 beta co-migrated on SDS-polyacrylamide gels as 17.5 kd polypeptides and reacted with specific polyclonal antisera raised to three synthetic peptides of human IL 1 beta in immunoblot experiments. Amino acid sequence analysis of rIL 1 beta showed that the native amino terminus, an ALA residue, was faithfully maintained. Purified native and rIL 1 beta co-chromatographed on reverse-phase HPLC. Specific biologic activities of rIL 1 beta were indistinguishable from those of the native protein in murine thymocyte and human dermal fibroblast proliferation assays, with half-maximal stimulation occurring at concentrations of 25 pM in the murine thymocyte assay and 2 pM in the human dermal fibroblast assay. Similarly, native and rIL 1 beta competed equally well for high affinity IL 1 receptor binding sites, each exhibiting a Ki of 20 pM on MRC-5 human embryonic lung fibroblasts. These observations indicate that E. coli efficiently expresses large quantities of rIL 1 beta, which emulates exactly the properties of the native protein.     

Production of a 26,000-dalton interleukin 1 inhibitor by human monocytes is regulated by granulocyte-macrophage colony-stimulating factor

An interleukin 1 (IL 1) inhibitor is secreted into culture medium by a human promyelocytic cell line, H-161, upon stimulation with (PMA) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Since the morphological characteristics of this cell line were macrophage-like, human monocytes were tested for their ability to produce similar activity using the same induction conditions. Upon induction of adherent peripheral blood monocytes with rhGM-CSF and/or PMA, an IL 1 antagonistic activity was found in the cell supernatants, as determined by IL 1 receptor binding assay, using the murine EL-4.6.1C10 cell line as the cell target. Most of the inhibition of IL 1 binding induced by PMA or by PMA/rhGM-CSF was shown to be caused by IL 1, since it was neutralized by a mixture of anti-IL 1 alpha/beta antibodies and was active in the murine thymocyte proliferation assay (LAF). The activity induced by GM-CSF alone was not neutralized by anti-IL 1 alpha/beta antibodies and showed no LAF activity. The IL 1 inhibitor activity was induced by rhGM-CSF with a D50 around 40 pg/ml. The activity was produced for more than 3 wk in the presence of GM-CSF; removal of GM-CSF was followed by a rapid decrease of IL 1 antagonistic activity. The specific binding of biosynthetically labeled IL 1 inhibitor to target cells (EL-4.6.1C10) showed a protein of 26 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This molecule shares biological and physical characteristics with the urinary IL 1 inhibitor and the promyelocytic H-161-derived IL 1 inhibitor.(ABSTRACT TRUNCATED AT 250 WORDS)     

Cytotoxic lymphokines produced by cloned human cytotoxic T lymphocytes. II. A novel CTL-produced cytotoxin that is antigenically distinct from tumor necrosis factor and alpha-lymphotoxin

We have cloned lines of IL 2-dependent human T cells derived from alloantigen, soluble antigen (tetanus toxoid), mitogen, or IL 2-stimulated peripheral blood lymphocytes and characterized their surface marker expression and cytolytic activity. The surface phenotype and cytolytic function was compared with the ability of these T cell clones to release cytotoxic lymphokines in response to mitogenic lectins. The cytotoxins released by these CTL clones were detected on the murine L929 target cells in a 16-hr assay. All of the T cell clones, whether stimulated by HLA alloantigens, tetanus toxoid, or mitogens, exhibited killer cell activity and the capacity to secrete a soluble cytotoxin(s). Specific polyclonal antisera to recombinant human tumor necrosis factor (rTNF) and human alpha-lymphotoxin (alpha LT) were unable to neutralize the cytotoxic activity released by most of these CTL clones. These results indicate that human CTL produce a novel antigenic form(s) of cytotoxin that we have termed CTL-toxin. Supernatants from several CTL clones yielded a cytotoxic activity that was partially neutralized (10 to 40%) by saturating levels of anti-TNF (but not anti-alpha LT) indicating that human CTL may be capable of producing a TNF-like molecule. Only two out of 60 CTL clones studied thus far produced a cytotoxic activity that was partially neutralized by anti-alpha LT (20 to 40%). Collectively, these results suggest that although both the CD4 and the CD8 subpopulations of human cytotoxic T cells may be capable of releasing several types of cytotoxins in response to mitogenic signals, the predominant cytotoxin is distinct from alpha LT and TNF.     

Membrane-associated interleukin 1 activity on human U937 tumor cells: stimulation of PGE2 production by human chondrosarcoma cells

Membrane-associated interleukin 1 (IL 1) activity was induced on the human macrophage tumor cell line, U937, by pretreatment with phorbol myristic acid (PMA). Incubation of PMA-treated, paraformaldehyde-fixed U937 cells with the murine cell line D10.G4.1 in the presence of concanavalin A caused an increase in DNA synthesis as measured by the uptake of tritiated thymidine. Paraformaldehyde-fixed U937, not pretreated with PMA, showed little or no activity. A rabbit polyclonal antibody directed against human IL 1 neutralized all membrane-associated IL 1-like activity, as measured by the inhibition of D10.G4.1 cell proliferation. PMA-treated U937 caused a pronounced enhancement of PGE2 production from a human chondrosarcoma cell line, SW-1353. Membrane-associated IL 1 induced a more potent PGE2 response than did a maximal concentration of soluble IL 1. Rabbit antihuman IL 1 neutralized membrane-bound IL 1 induction of PGE2. The data presented here raise the possibility that membrane-bound IL 1 may play a primary role in the pathophysiology of the inflammatory disease process.